2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.
BackgroundWound healing events (WHE) are probably the most common type of post-transplant (Tx) surgical complication. Due to its antiproliferative properties, mammalian target of rapamycin inhibitors…2016 American Transplant Congress
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.
Introduction:Pre-Transplant Microbead donor HLA specific antibody(DSA) positive but cell crossmatch negative transplants are considered to be at increased immunological risk. This study aimed to address…2016 American Transplant Congress
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.
Antibody-mediated rejection (AMR) is a major cause of late renal allograft failure. The benefit of treatment of chronic ABMR is unknown. Currently there is no…2016 American Transplant Congress
Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.
Introduction: Pre-transplant IgG antibody screening is common due to its established role of predicting rejection and graft survival; the role of pre-formed IgM human leukocyte…2016 American Transplant Congress
Donor-Specific Antibodies in a Single-Center Pediatric Kidney Transplant Population – Incidence and Risk Factors.
In mid-2015, we implemented donor-specific antibody (DSA) monitoring in our pediatric kidney transplant recipient (pKTR) population as recommended (Transplantation 2013;95:19-). We now cross-sectionally analyzed our…2016 American Transplant Congress
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.
Pharmacy, Oregon Health & Science University, Portland, OR.
Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…2016 American Transplant Congress
P-Glycoprotein Function: Association with Race, Gender and Tacrolimus Pharmacokinetics.
Background: Long term allograft survival remains poorer in African American(AA) renal transplant recipients(RTR) compared to Caucasians(C) and may be due to racial differences in calcineurin…2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…2016 American Transplant Congress
Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.
Background:The ability of regulatory T cells (Treg) to prolong allograft survival and promote transplant tolerance in lymphodepleted rodents is well-established. Few studies have addressed the…
- « Previous Page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- …
- 138
- Next Page »